Filtered By:
Source: Advances in Therapy
Drug: Warfarin
Countries: USA Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
ConclusionsThese results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity and polypharmacy in a commercially-insured US population.
Source: Advances in Therapy - May 25, 2021 Category: Drugs & Pharmacology Source Type: research
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
ConclusionIn the real-world setting, patients with NVAF newly treated with apixaban were less likely to switch or discontinue treatment compared to patients treated with rivaroxaban or dabigatran.FundingPfizer and Bristol-Myers Squibb.
Source: Advances in Therapy - November 29, 2018 Category: Drugs & Pharmacology Source Type: research
